Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 4/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.33 |
| ▸ | ORAI2 | Q96SN7 | 3/20 | 0.33 |
| ▸ | ORAI3 | Q9BRQ5 | 3/20 | 0.33 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.33 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274031 | 0.90 | TRPV6 (0.41) | TSHRTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL2399166 | 0.85 | TSHR (0.50) | ENPP2TSHRTRPV6ORAI1ORAI2 | |
| SCHEMBL2399007 | 0.84 | TRPV6 (0.52) | ENPP2TSHRTRPV6ORAI1ORAI2 | |
| SCHEMBL2399046 | 0.81 | ORAI1 (0.41) | TSHRTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL3282237 | 0.80 | TRPV6 (0.52) | ENPP2TSHRTRPV6ORAI1ORAI2 | |
| SCHEMBL14135196 | 0.78 | LPL (0.41) | ENPP2TRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL14503425 | 0.77 | ORAI1 (0.59) | ENPP2TSHRTRPV6ORAI1ORAI2 | |
| SCHEMBL2398396 | 0.77 | ENPP2 (0.47) | ENPP2IDO1AGXTMAOB | |
| SCHEMBL2400576 | 0.76 | ENPP2 (0.32) | ENPP2TRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL2406696 | 0.76 | ENPP2 (0.36) | ENPP2TSHRTRPV6ORAI1ORAI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | claimed |
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | ENPP2 3251/4885TSHR 2155/4885TRPV6 4868/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | ENPP2 3574/4885TSHR 977/4885TRPV6 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.